LOSANGELES — Craig Gelfound, head of Arent Fox LLP’s Intellectual Property practice in Los Angeles, has once again been honored by the Daily Journal as one of the Top Intellectual Property Lawyers in California, marking his ninth consecutive year of this recognition.
On March 26 Arent Fox together with the Loyens & Loeff Life Sciences Team will organize an afternoon seminar about the patenting of Life Sciences and Food-related inventions in the U.S.
De Gaulle Fleurance & Associés & Arent Fox are pleased to invite you to a breakfast-conference entitled, “Patent Ownership and Salaried Investors: French-US Perspective.”
Arent Fox has successfully procured another patent for Acronis, a leading provider of cloud backup and data management services, covering a new technology for watermarking digital content using a blockchain network.
The United States Patent and Trademark Office greeted the new year with a welcome gift: “2019 Revised Patent Subject Matter Eligibility Guidance” that updates the framework on subject matter eligibility under 35 U.S.C. § 101.
Schiff Hardin successfully secured a favorable outcome for our client, Fresenius Kabi USALLC, in a patent-infringement suit filed by Hospira Inc., which paves the way for Fresenius to market a new generic drug.
Joel Wallace was quoted on a recent ruling from Federal Judge Reed O’Connor in the Federal District Court in Fort Worth, Texas, that the Affordable Care Act’s (ACA) individual coverage mandate is unconstitutional and, in the absence of the individual mandate, the rest of the ACA cannot stand.
Arent Fox has successfully procured a patent for Acronis, a leading provider of cloud backup and cyber protection, for a new technology of verifying data integrity using a blockchain network.
In the quick pound of a gavel, the entire U.S. pharmaceutical and biologics industries were thrown into doubt after Judge Reed O’Connor of the United States District Court for the Northern District of Texas found the individual mandate of the Affordable Care Act (ACA) – and therefore the entire act – unconstitutional.
Intellectual Property Practice Group Co-Leader Imron Aly was quoted on how including patents in the U.S. Food and Drug Administration’s “Purple Book” — which lists biological products, including any biosimilar and interchangeable biological products — might affect developers.
Bitcoin cryptocurrency and other cryptocurrencies have experienced immense growth, as demonstrated by the skyrocketing values and development of technical solutions involving blockchain technologies.
Intellectual Property Practice Group Co-Leader Imron Aly described the three key features of the U.S. Food and Drug Administration’s Biosimilar Action Plan: education, interchangeability, and international data sharing.
Today’s oral arguments in Supreme Court case Helsinn Healthcare v. Teva illustrate the power that a successful appeal could have to change a longstanding doctrine and significantly impact how businesses handle intellectual property transactions.
Hatch-Waxman and Biosimilars Practice Group Leader Imron Aly was quoted on why patients in the United States may have to wait longer than those in the European Union for the biosimilar adalimumab, referencing the brand name drug, Humira.
Starting on January 1, 2020, automotive dealers will need to comply with the strongest online privacy law in the United States, the California Consumer Privacy Act of 2018.
Intellectual Property Practice Group Co-Leader Imron Aly spoke with The Center for Biosimilars on key takeaways from the long-running case Saint Regis Mohawk Tribe, Allergan v. Mylan
